Lonza expands cell-biology platform by acquiring Simbiosys Biowares’ preclinical cell and molecular biology group
“We are happy to acquire the preclinical cell and molecular biology group of Simbiosys Biowares India, as it is aligned with Lonza’s strategy to continue to develop its life-science platform and to expand its global cell-biology portfolio. The deal further strengthens Lonza’s position as a worldwide leader in cell discovery by integrating a unique service model into its portfolio and by continuing to develop the company’s activities”, comments Anja Fiedler, Head of Lonza Bioscience. “The skilled R&D staff nicely complements our existing R&D capabilities in Cell Discovery”.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.